Inclusion Criteria:

        Criteria for the multiple myeloma cohort

          -  Patients with histologically or pathologically diagnosed multiple myeloma

          -  Patients who achieved CR, sCR, VGPR, and PR with induction therapy Criteria for the
             malignant lymphoma cohort

          -  Patients with histologically or pathologically diagnosed malignant lymphoma

          -  First or second CR or PR Multiple myeloma cohort, malignant lymphoma cohort common
             criteria

          -  Patients aged 20 to 75 years or younger at the time of informed consent

        Exclusion Criteria:

          -  Those who received allogeneic hematopoietic stem cell transplantation (Allo-SCT),
             autologous hematopoietic stem cell transplantation (ASCT), or CAR-T therapy

          -  Patients who have developed adverse events leading to discontinuation of hematopoietic
             stem-cell collection due to administration of granulocyte colony-stimulating factor
             (G-CSF) or apheresis

          -  Patients who have not been able to collect adequate amounts of hematopoietic stem
             cells with G-CSF or plerixafor administration

          -  Patients with hypersensitivity to G-CSF or plerixafor

          -  Patients with ECOG Performance status (PSs) of 2 or greater.

          -  Patients whose cardiac or pulmonary conditions were judged to be inappropriate for
             apheresis or ASCT.

          -  Pregnant or breastfeeding female patients